Processa Pharmaceuticals, Inc.
PCSAProcessa Pharmaceuticals, Inc. in brief
Processa Pharmaceuticals, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. Its market value was $5 M on 30 October 2026, which makes it the 26,844th largest listed company in the world and the 4,399th largest in the USA on this site. George K. Ng is its chief executive. Its shares trade under the symbol PCSA (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on March 29, 2011. Our principal executive office is located at 601 21st Street, Suite 300 Vero Beach, FL 32960. Our telephone number is (772) 453-2899.
We make available free of charge on or through our Internet website (http://www.processapharmaceuticals.com) our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC), as well as our Code of Ethics and Code of Conduct. The SEC also maintains a website which provides online access to reports and other information regarding registrants that file electronically with the SEC at: www.sec.gov.
From the company's annual report filed with the US SEC: read the report
Processa Pharmaceuticals, Inc. timeline
- 2011
- β’Β· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- βRenamed Processa Pharmaceuticals, Inc.Formerly Heatwurx, Inc..
Events of Processa Pharmaceuticals, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,629 (Jan 2022) Β· #5,304 (Dec 2022) Β· #5,392 (Jul 2023) Β· #4,534 (Jan 2024) Β· #2,429 (Mar 2026) Β· #4,073 (Aug 2026) Β· #4,358 (Oct 2026) Β· #4,397 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- β
- Price / book
- 0.9Γ
- Free cash flow yield
- -212.7%
- Net margin
- β
- Operating margin
- β
- Return on equity
- -243.0%
- Liabilities / assets
- 28.7%
- Revenue growth
- 0.0%
- R&D / revenue
- 27.3%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | β | β | $-14M | $-14M | β |
| Dec 2024 | β | β | $-12M | $-12M | β |
| Dec 2023 | β | β | $-11M | $-11M | β |
| Dec 2022 | β | β | $-28M | $-27M | β |
| Dec 2021 | β | β | $-12M | $-11M | β |
| Dec 2020 | β | β | $-15M | $-14M | β |
| Dec 2019 | β | β | $-4M | $-3M | β |
| Dec 2018 | β | β | $-5M | $-4M | β |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-11M | β | β | $-10.36 | β |
| Dec 2024 | $-11M | $0M | $-11M | $-96.78 | β |
| Dec 2023 | $-8M | $0M | $-8M | $-8.48 | β |
| Dec 2022 | $-10M | β | β | $-34.05 | β |
| Dec 2021 | $-9M | β | β | $-0.75 | β |
| Dec 2020 | $-3M | β | β | $-2.54 | β |
| Dec 2019 | $-3M | β | β | $-0.70 | β |
| Dec 2018 | $-4M | β | β | $-0.71 | β |
Quarterly results
Latest quarter to Sep 2026: revenue β, net income $-183M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 13, 202610-QQuarterly report Β· period to Sep 2026
- Nov 5, 20268-KCurrent reportOther events
- Nov 4, 20268-KCurrent reportDirectors or officers changed Β· Other events
- Oct 29, 20268-KCurrent reportOther events
- Oct 22, 2026DEF 14AProxy statement
- Oct 5, 20268-K/ACurrent report (amended)Other events
- Aug 14, 202610-QQuarterly report Β· period to Jun 2026
- Aug 4, 20268-KCurrent reportDirectors or officers changed Β· Shareholder vote
- Jul 29, 20268-KCurrent reportMaterial agreement Β· Agreement ended Β· Acquisition or disposal completed Β· Unregistered share sale Β· Directors or officers changed Β· Bylaws amended Β· Regulation FD disclosure
- Jun 18, 2026DEF 14AProxy statement
- May 7, 202610-QQuarterly report Β· period to Mar 2026
- Apr 30, 202610-K/AAnnual report (amended) Β· period to Dec 2025
Official filings of Processa Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- β
- Operating income
- $-14 M
- Net income
- $-14 M
For year ending December-2025 Β· source: SEC filing
Balance sheet
- Total assets
- $8 M
- Total liabilities
- $2 M
- Total equity
- $6 M
As of December-2025
Top 18 institutional investors in Processa Pharmaceuticals, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners GP, L.L.C. | 3,275,493 | New | 117.26% | $5 M | Nov 16, 2026 |
| 2 | Soleus Capital Management, L.P. | 160,943 | New | 5.76% | $0 M | Nov 16, 2026 |
| 3 | Connective Capital Management, LLC | 85,274 | 0 (0.00%) | 3.05% | $0 M | Nov 16, 2026 |
| 4 | Citadel Advisors LLC | 58,629 | +37,323 (+175.18%) | 2.10% | $0 M | Nov 16, 2026 |
| 5 | Geode Capital Management, LLC | 31,252 | +9,162 (+41.48%) | 1.12% | $0 M | Nov 6, 2026 |
| 6 | Seven Fleet Capital Management LP | 18,300 | New | 0.66% | $0 M | Nov 16, 2026 |
| 7 | Janus Henderson Group Ltd. | 18,016 | β | 0.65% | $0 M | Nov 16, 2026 |
| 8 | Jane Street Group, LLC | 13,571 | +307 (+2.31%) | 0.49% | $0 M | Nov 12, 2026 |
| 9 | Vanguard Capital Management LLC | 12,729 | 0 (0.00%) | 0.46% | $0 M | Nov 13, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 10,857 | 0 (0.00%) | 0.39% | $0 M | Nov 13, 2026 |
| 11 | UBS Group AG | 6,774 | -1,020 (-13.09%) | 0.24% | $0 M | Nov 10, 2026 |
| 12 | Millennium Management LLC | 1,875 | New | 0.07% | $0 M | Nov 16, 2026 |
| 13 | Tower Research Capital LLC (TRC) | 419 | -2,080 (-83.23%) | 0.01% | $0 M | Nov 16, 2026 |
| 14 | Robinhood Markets, Inc. | 59 | β | 0.00% | $0 M | Nov 18, 2026 |
| 15 | Jpmorgan Chase & Co | 18 | New | 0.00% | $0 M | Nov 12, 2026 |
| 16 | Jones Financial Companies Lllp | 7 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 17 | FMR LLC | 6 | New | 0.00% | $0 M | Nov 10, 2026 |
| 18 | Barclays PLC | 3 | New | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Processa Pharmaceuticals, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| πΊπΈ Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 14,221 | $0 M | 0.51% | <0.01% | β3.0% | May 31, 2026 |
| πΊπΈ Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 12,729 | $0 M | 0.46% | <0.01% | no change | Jun 30, 2026 |
| πΊπΈ Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 2,088 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| πΊπΈ Fidelity Total Market Index FundFidelity Management & Research Company LLC | 969 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
As of Jun 30, 2026
Insider trading at Processa Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | George K. NgChief Executive Officer, Director | Option exercise | +1,600 | β | β | 17,092 | Form 4 |
| filed | George K. NgChief Executive Officer, Director | Buy | +3,057 | $1.930 | $6 K | 15,492 | Form 4 |
| filed | David YoungPres. Research & Development, Director | Buy | +2,531 | $1.930 | $5 K | 21,729 | Form 4 |
| filed | Patrick LinChief Business - Strategy Off | Buy | +2,106 | $1.930 | $4 K | 13,113 | Form 4 |
| filed | Russell SkibstedChief Financial Officer | Buy | +3,277 | $1.930 | $6 K | 16,689 | Form 4 |
| filed | Wendy GuyChief Administrative Officer | Buy | +2,436 | $1.930 | $5 K | 14,394 | Form 4 |
| filed | Justin W. YorkeDirector | Option exercise | +203 | β | β | 353 | Form 4 |
| filed | James R. NealDirector | Option exercise | +203 | β | β | 1,021 | Form 4 |
Markets and events: Processa Pharmaceuticals, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-10-09 14:28 UTC, code LUDP, resumed 14:33 UTC
- 2025-12-17 20:51 UTC, code LUDP, resumed 21:00 UTC
- 2025-12-17 20:09 UTC, code LUDP, resumed 20:14 UTC
- 2025-12-17 17:50 UTC, code LUDP, resumed 17:55 UTC
- 2025-12-17 16:42 UTC, code LUDP, resumed 16:47 UTC
Fails to deliver
- : 100 shares at $1.89
- : 100 shares at $1.85
- : 2,778 shares at $1.82
- : 100 shares at $1.80
- : 100 shares at $1.81
Processa Pharmaceuticals, Inc. scorecard#
Passes 3 of the 10 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 3
Growth1 of 2
Profitability0 of 3
Financial health1 of 2
Shareholder returnsnot known
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Processa Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | β | β | β | 0 | 0 | β | β | β | β | 0.0 | |
| Gross profit | β | β | β | β | β | β | β | β | β | 0.0 | |
| Research and development | 7.8 | 7.3 | 5.8 | 11 | 6.9 | 3.2 | 2.3 | 3.1 | 1.0r | 1.5r | |
| Selling, general and administrative | β | β | β | β | β | β | β | 1.4 | 0.8 | 0.1 | |
| General and administrative | 6.2 | 4.8 | 5.7 | 8.8 | 4.7 | 3.3 | 1.6 | 1.4 | β | β | |
| Operating expenses | β | β | β | β | β | β | β | β | 1.8 | 1.9r | |
| Operating income | β14 | β12 | β11 | β28 | β12 | β15 | β3.9 | β4.5 | β1.8 | β1.9 | |
| Interest and finance income | 0.1 | 0.2 | 0.3 | 0.1 | 0.0r | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest expense and finance costs | β | β | β | β | 0.0 | 0.3 | 0.0 | 0.2 | 0.1 | 0.2 | |
| Income before tax | β14 | β12 | β11 | β27 | β12 | β15 | β4.0 | β4.7 | β1.9 | β0.3 | |
| Income tax | β | β | β | β | β0.5 | β1.0 | β0.6 | β0.9 | 0.3 | β | |
| Income from continuing operations | β | β | β | β | β | β | β | β | β1.9 | β1.9r | |
| Income from discontinued operations | β | β | β | β | β | β | β | β | β | 0.0 | |
| Net income attributable to shareholders | β14 | β12 | β11 | β27 | β11 | β14 | β3.4 | β3.8 | β1.9 | β1.9r | |
| Earnings per share, basic | -10.36 | -96.78r | -8.48 | -34.05r | -0.75 | -2.54 | -0.70 | -0.71r | -0.06 | -0.07r | |
| Earnings per share, diluted | -10.36 | -96.78r | -8.48 | -34.05 | -0.75 | -2.54 | -0.70 | -0.71r | -0.06 | -0.07r | |
| Shares, weighted average (basic) | 1.3 | 0.1r | 1.3 | 0.8r | 15 | β | β | β | 33 | 29 | |
| Shares, weighted average (diluted) | 1.3 | 0.1r | 1.3 | 0.8 | 15 | 7.5 | 5.5r | 5.3r | 33 | 29r | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 5.5r | 1.2 | 4.7 | 6.5 | 16 | 15 | 0.7 | 1.7 | 2.8 | 1.1r | |
| Other current assets | 0.1r | 0.7r | 0.9 | 1.9 | 1.8 | 0.6 | 0.3 | 0.3 | β | β | |
| Current assets | 5.7r | 1.9r | 5.6 | 8.4 | 18 | 16 | 1.0 | 2.0 | 3.0 | 2.3r | |
| Property, plant and equipment | 0.0r | 0.0 | 0.0 | β | β | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Right-of-use (leased) assets | β | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.2 | β | β | β | |
| Other intangible assets | β | β | β | β | 8.1 | 8.8 | 9.6 | 10 | β | β | |
| Non-current assets | β | 1.3 | β | 0.2 | 8.1 | β | β | β | β | β | |
| Total assets | 7.8r | 3.2 | 5.8 | 8.6 | 26 | 25 | 11 | 12r | 3.0 | 2.4r | |
| Accounts payable | 1.1r | 0.9 | 0.3 | 0.3 | 0.2 | 0.3 | 0.1 | 0.3 | 0.1 | 0.0r | |
| Debt due within a year | β | β | β | β | β | β | β | 0.2 | 2.4 | β | |
| Current liabilities | 2.2r | 1.5 | 0.7 | 1.0 | 1.0 | 1.2 | 1.2 | 0.6 | 2.6 | 0.1r | |
| Lease liabilities (non-current) | β | β | 0.1 | 0.2 | 0.0 | 0.1 | 0.1 | β | β | β | |
| Total liabilities | 2.2r | 1.5 | 0.8 | 1.1 | 1.0 | 2.3 | 2.9 | 2.8r | 2.6 | 0.1r | |
| Retained earnings | β101r | β87 | β75 | β64 | β37 | β25 | β11 | β7.6 | β3.9 | β2.0r | |
| Shareholders' equity | 5.6r | 1.7r | 5.0 | 7.5 | 25 | 23r | 8.0 | 9.7 | 0.4r | β2.3r | |
| Total liabilities and equity | 7.8r | 3.2 | 5.8 | 8.6 | 26 | 25 | 11 | 12r | 3.0 | 2.4r | |
| Shares outstanding | 2.6 | 0.1r | 1.3 | 0.8r | 16 | 14r | 5.5r | 5.5r | 35 | 32r | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 0.9 | 0.6 | 1.1 | 8.8 | 3.4 | 2.7 | 0.5 | 0.1 | β | 0.0 | |
| Cash from operating activities | β11 | β11 | β8.1 | β9.6 | β8.7 | β3.1 | β2.8 | β3.7 | β1.7 | β2.2r | |
| Capital expenditure | β | β0.0 | β0.0 | β | β | β | β | β | β0.0 | β0.0 | |
| Intangible assets bought | β | β | β | β | β | β | β | β0.0r | β | β | |
| Cash from investing activities | β0.9 | β0.0 | β0.0 | β | β | β | β | β0.0 | 1.0 | β1.0r | |
| Shares issued | 17 | 7.8 | 6.3 | 6.4 | 10 | 17 | β | 2.9 | β | 4.3 | |
| Cash from financing activities | 17 | 7.7 | 6.3 | β0.4 | 9.8 | 18 | 1.7 | 2.6 | 2.4 | 4.3r | |
| Change in cash | 4.3 | β3.5 | β1.8 | β10.0 | 1.1 | 15 | β1.0 | β1.1 | 1.8 | 1.1r | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
Executive pay at Processa Pharmaceuticals, Inc.#
From the pay-versus-performance table of the company's proxy statement. βActually paidβ marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025George Ng | $673 K | $565 K | $531 K | $2 |
| 2024George Ng | $521 K | $288 K | $286 K | $13 |
| 2023George Ng | $473 K | $429 K | $322 K | $100 |
As of Dec 31, 2025
Events at Processa Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 Β· Acquisition or sale completed 1 Β· Directors and officers 4 Β· Material agreement 7 Β· Agreement ended 2 Β· Unregistered share sale 3 Β· Shareholder rights changed 1 Β· Bylaws or fiscal year changed 3 Β· Shareholder vote 8
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementAgreement endedUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Agreement ended | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K/A | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementUnregistered share sale | 8-K/A | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreementShareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K |
As of Nov 4, 2026
Acquisitions and funding#
1 acquisitions, $3 M paid where reported Β· 2 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Asset Purchase Agreement | 2011 | β | $3 M | β | Annual report |
Private share sales Β· funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2021 | $10 M | Private placement after listing | $10 to $50 million | 18 | equity, options | SEC |
| May 2018 | $3 M | Private placement after listing | $2 to $10 million | 33 | equity, options | SEC |
| Jul 2013 | $2 M | No. 2 | $2 to $10 million | 51 | equity, options | SEC |
| Aug 2012 | $2 M | No. 1 | Under $2 million | 44 | equity | SEC |
How Processa Pharmaceuticals, Inc. compares in Biotechnology
- Market cap$5 M Β· higher than 6% of 726
- Revenue growth0.0% Β· higher than 42% of 439
- Price / book0.9Γ Β· lower than 80% of 532
Peer comparison Β· Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Processa Pharmaceuticals, Inc.πΊπΈ | $5 M | β | β | 0.0% |
| Novo Nordisk A/Sπ©π° | $203.2 B | 13.1Γ | 33.1% | +10.8% |
| Vertex Pharmaceuticals IncorporatedπΊπΈ | $134.3 B | 33.8Γ | 30.7% | +8.9% |
| Moderna, Inc.πΊπΈ | $90.1 B | β | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.πΊπΈ | $84.1 B | 17.5Γ | 28.5% | +1.0% |
| Argenx SEπ³π± | $52.8 B | 40.9Γ | 31.1% | +89.9% |
| CSL Limitedπ¦πΊ | $51.6 B | β | -16.4% | β |
| Samsung Biologics Co., Ltd.π°π· | $51.5 B | 40.5Γ | 39.2% | β |
| UCB SAπ§πͺ | $48.6 B | 26.3Γ | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
How current the figures are
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Processa Pharmaceuticals, Inc.? Verify and update this profile β free
Show Processa Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.